8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 11, 2026·SEC
Royalty Pharma plc(RPRX)Earnings, Financials & Key Ratios
RPRX•NASDAQ
$57.80
32.1× P/E·Price updated Jul 7, 2026
AboutRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Show more
- Revenue$2.38B+5.1%
- EBITDA$1.56B+0.5%
- Net Income$771M-10.2%
- EPS (Diluted)1.80-5.8%
- Gross Margin100%
- EBITDA Margin65.74%-4.4%
- Operating Margin65.58%+14.8%
- Net Margin32.42%-14.6%
- ROE7.69%-8.6%
RPRX Price & Volume
Royalty Pharma plc (RPRX) stock price & volume — 10-year historical chart
Loading chart...
Royalty Pharma Faces Patent Cliff Reinvestment Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strong
Financial:Adequate
Cash Flow:Robust
Primary Risk:Patent cliff reinvestment risk
Key Thesis Takeaways
- Royalty Pharma maintains a unique business model characterized by 100% gross margins, yet the firm faces significant pressure to deploy capital effectively to offset the inevitable decay of its aging blockbuster drug portfolio.
- While the company demonstrates robust cash generation, investors should monitor the rising debt load, which has increased to $9.0 billion as of 2026Q1, and the potential for earnings volatility driven by lumpy milestone payments.
- Long-term value creation remains contingent on management's ability to acquire new royalty streams that can successfully replace expiring assets without overleveraging the balance sheet.
Verdict Logic
while the company offers a 1.2% dividend yield and strong cash conversion, the high forward P/E of 10.96 and significant reinvestment risk warrant a cautious approach until the long-term sustainability of the royalty portfolio is better established.
RPRX Growth Metrics
Royalty Pharma plc (RPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years2.3%
3 Years2.06%
TTM7.82%
Profit CAGR
10 Years-
5 Years-4.59%
3 Years162.07%
TTM-24.25%
EPS CAGR
10 Years-
5 Years7.06%
3 Years162.07%
TTM-23.71%
Return on Capital
10 Years10.2%
5 Years7.27%
3 Years8.61%
Last Year8.68%
RPRX Recent Earnings
Royalty Pharma plc (RPRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$1.30+7.4%
$1.21
Rev
$925M+4.9%
$882M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$1.46+13.2%
$1.29
Rev
$874M+8.3%
$807M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.17+17.7%
$0.99
Rev
$609M-15.1%
$717M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.14+10.7%
$1.03
Rev
$579M-14.0%
$673M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.30vs $1.21+7.4% | $925Mvs $882M+4.9% |
| Q1 2026 | Feb 11, 2026 | $1.46vs $1.29+13.2% | $874Mvs $807M+8.3% |
| Q4 2025 | Nov 5, 2025 | $1.17vs $0.99+17.7% | $609Mvs $717M-15.1% |
| Q3 2025 | Aug 6, 2025 | $1.14vs $1.03+10.7% | $579Mvs $673M-14.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Royalty Pharma plc (RPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $57.80 | $24.76B | 32.11 | 5.06% | 32.42% | 7.69% | 1.17% | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $30.11 | $5.64B | 27.13 | 47.52% | 78.1% | 16.55% | — | |
| $111.89 | $50.81B | 34.01 | 83.33% | 65.55% | 21.33% | — | |
| $196.61 | $13.65B | 29.39 | 44.57% | 48.53% | 11.85% | — | |
| $209.60 | $40.41B | 35.77 | 63.69% | 65.12% | 18.68% | — |
Compare RPRX vs Peers
Royalty Pharma plc (RPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RPRX SEC Filings & Documents
Royalty Pharma plc (RPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RPRX Frequently Asked Questions
Royalty Pharma plc (RPRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Royalty Pharma plc's revenue?
Royalty Pharma plc (RPRX) reported $2.44B in revenue for fiscal year 2025. This represents a 53% increase from $1.60B in 2017.
How fast is Royalty Pharma plc growing?
Royalty Pharma plc (RPRX) grew revenue by 5.1% over the past year. This is steady growth.
Is RPRX profitable?
Yes, Royalty Pharma plc (RPRX) is profitable, generating $827.6M in net income for fiscal year 2025 (32.4% net margin).
Dividend & Returns
Does RPRX pay dividends?
Yes, Royalty Pharma plc (RPRX) pays a dividend with a yield of 1.17%. This makes it attractive for income-focused investors.
What is RPRX's return on equity?
Royalty Pharma plc (RPRX) has a return on equity (ROE) of 7.7%. This is below average, suggesting room for improvement.
What is Royalty Pharma plc's free cash flow?
Royalty Pharma plc (RPRX) generated $2.65B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.